Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/jmv.26191

http://scihub22266oqcxt.onion/10.1002/jmv.26191
suck pdf from google scholar
32628003!7323415!32628003
unlimited free pdf from europmc32628003    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32628003      J+Med+Virol 2020 ; 92 (11): 2813-2820
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Tocilizumab in patients with severe COVID-19: A single-center observational analysis #MMPMID32628003
  • Knorr JP; Colomy V; Mauriello CM; Ha S
  • J Med Virol 2020[Nov]; 92 (11): 2813-2820 PMID32628003show ga
  • Patients with coronavirus disease 2019 (COVID-19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, may be beneficial for severe COVID-19, when cytokine storm is suspected. This is a retrospective single-center analysis of the records of patients diagnosed with COVID-19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen-support at 24, 48, and 72 hours, and 7, 14, and 28 days post-tocilizumab, are reported. Patients were evaluated by baseline pre-tocilizumab oxygenation status and changes in proinflammatory markers within 7 days post-tocilizumab are reported. Sixty-six patients received tocilizumab at a mean dose of 724 mg (7.4 mg/kg), 3.7 days from admission. At baseline, 53% of patients were on ventilation support and all had elevated proinflammatory markers, including c-reactive protein (CRP). Common comorbidities were diabetes mellitus (43%) and hypertension (74%). Most patients received concomitant glucocorticoids and hydroxychloroquine. Seven days after tocilizumab, ten patients (15.2%) had clinical improvement in their oxygenation status, and there was a 95% decrease in CRP. Within 14 days of treatment, 29% of patients had clinical improvement, 20% had minimal or no improvement, 17% worsened, 27% died, and 7% were transferred to an outside hospital. Ultimately, 42% of all patients that received tocilizumab expired and 49% were discharged. This study found limited clinical improvement in patients that received tocilizumab in the setting of severe COVID-19. Clinical trials are ongoing to further evaluate tocilizumab's benefit in this patient population.
  • |*COVID-19 Drug Treatment[MESH]
  • |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH]
  • |Arthritis, Rheumatoid/drug therapy[MESH]
  • |C-Reactive Protein/analysis[MESH]
  • |Cohort Studies[MESH]
  • |Cytokine Release Syndrome/drug therapy[MESH]
  • |Ferritins/blood[MESH]
  • |Fibrin Fibrinogen Degradation Products/analysis[MESH]
  • |Humans[MESH]
  • |L-Lactate Dehydrogenase/blood[MESH]
  • |Oxygen/administration & dosage[MESH]
  • |Receptors, Interleukin-6/antagonists & inhibitors[MESH]
  • |Respiration, Artificial[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box